DexCom Inc. (DXCM)
The price, the headline numbers and the latest news, in one place.
DexCom Inc. (DXCM) Stock Price, Analysis & Data
| Bid | 83.86 |
| Market Cap | 34.85B |
| Revenue (ttm) | 4.97B |
| Net Income (ttm) | 999.7M |
| 1.41 | |
| 2.53 | |
| 36.5 | |
| 29.55 | |
| P/B (ttm) | 13.29 |
| P/S (ttm) | 7.01 |
| Earnings Date | Oct 29, 2026 |
| Ask | 97.15 |
| Volume | 3,478,990 |
| Avg. Volume (20D) | 5,235,919 |
| Open | 89.61 |
| Previous Close | 90.22 |
| Day's Range | 89.20 - 92.56 |
| 52-Week Range | 54.11 - 92.56 |
| Analyst | Strong Buy |
| Price Target | 94 (1.80%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions;...
Financial Performance
In 2025, DexCom's revenue was 4.66B, an increase of 15.6% compared to the previous year's 4.03B. Earnings were 836.3M, an increase of 45.14%.
Financial StatementsAnalyst Forecast
According to 25 analyst ratings, the average rating for DXCM stock is "Strong Buy". The 12-month stock price forecast is 94, which is upside of 1.8% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $1.31B misses estimates by $0, with 13.08% YoY growth.
- EPS of 0.7 exceeds estimates by 0.09, with 45.83% YoY growth.
Analysts project revenue of ... Upgrade
